Study finds mebufotenin nasal spray reduces depression
“In adults with treatment-resistant depression, single doses of intranasal mebufotenin benzoate were well tolerated and produced rapid, robust, and durable reductions in depressive symptoms,” the study authors write in a clinical trial published in the Journal of the American Medical Association on October 26, 2026. A recent clinical trial reported that a fast-acting synthetic nasal spray derived from a psychedelic compound found in the Sonoran Desert toad offers new hope for patients who have not found relief through traditional medications.
- A synthetic nasal spray containing mebufotenin (5-MeO-DMT), a psychedelic compound originally found in the venom of the Sonoran Desert toad, was evaluated in a phase 2b clinical trial involving 193 adults with treatment-resistant depression.
- Patients receiving single 8 mg or 12 mg doses experienced significant symptom reductions and rapid recovery times, with most individuals ready for discharge within two hours.
- The trial was funded by biotech firm AtaiBeckley, a subsidiary of pharmaceutical giant Eli Lilly and Company, as researchers look toward larger phase 3 trials required for regulatory approval.
Researchers Study Mebufotenin for Treatment Resistant Depression
Rates of depression remain high, with roughly one in six American adults experiencing the disorder, and approximately 30% of those individuals trying multiple medications without success. While first-line treatments continue to include standard talk therapy and traditional antidepressants, investigators are increasingly examining alternative approaches, including FDA-approved ketamine, dietary supplements like creatine, and an EEG helmet paired with a video-game like training. The latest clinical drug under study is mebufotenin, also known as 5-MeO-DMT, which belongs to the same chemical family as serotonin.
NewsNation noted that the study included 193 adults aged 18 to 75 across the United States, Europe, and Australia who had tried at least two prior antidepressants without experiencing sufficient symptom relief. Researchers divided participants into groups receiving randomized single doses of a nasal spray containing either a low control dose of 0.3 mg, a medium dose of 8 mg, or a high dose of 12 mg. Throughout the process, patients received psychological support before, during, and after treatment to monitor safety and efficacy.
Symptom Reductions and Duration of Relief
Participants in both the 8 mg and 12 mg groups showed significant improvements in their depression scores over the following weeks. The People’s Pharmacy detailed that investigators assessed outcomes using the Montgomery-Åsberg Depression Rating Scale, where higher numbers indicate more severe symptoms. After four weeks, patients on the 12 mg dose dropped an average of 11.1 points, while the 8 mg cohort saw an even larger average reduction of 12.5 points. By comparison, participants on the 0.3 mg control dose dropped an average of 5.5 points.
Among those who received the 8 mg dose, a quarter achieved clinical remission, meaning their symptoms fell below the diagnostic threshold for qualifying depression. Recovery benefits appeared rapidly, with reductions in depression scores recorded between day two and day 57 following the single administration.
Most Mebufotenin Side Effects Are Mild or Moderate
Adverse events were common during the trial, affecting 76% of patients in the 8 mg group and 85% of those in the 12 mg group. ScienceAlert reported that 99.7% of these reported events were classified as mild or moderate, including nasal discomfort, nausea, vomiting, headaches, tingling sensations, and excessive saliva. Side effects were also frequent in the low-dose control group, where 73% of participants reported adverse events, and one patient experienced two severe panic attacks during treatment.
A notable advantage of mebufotenin compared to other psychedelic treatments is its short duration. Between 78% and 85% of patients were able to leave the clinical facility within two hours of dosing. By contrast, psilocybin treatments can last over six hours, while the FDA-approved non-psychedelic nasal spray esketamine requires at least two hours of clinical monitoring.
Laboratory Synthesis Protects Wild Toad Populations
The compound used in the nasal spray is synthesized entirely in a laboratory, meaning no wild toad populations are harvested or harmed to produce the medication. Psychopharmacology researcher Chittaranjan Andrade of India’s National Institute of Mental Health and Neurosciences noted that single-day dosing with mebufotenin appears effective across challenging depressive disorders, with benefits sustaining for months. However, the current phase 2b trial is only an intermediate step designed to establish safety and efficacy parameters before moving forward.
Before any drug reaches the commercial market, it must successfully complete phase 3 clinical trials, which represent the largest phase required to gather definitive evidence for regulatory review. Psychiatrists managing treatment-resistant cases continue to monitor these developments while evaluating existing clinical protocols for patients who fail to respond to standard care.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.